Chinese Academy of

Iparomlimab and Tuvonralimab Injection (QL1706) is a combination therapeutic candidate under development by Xiyuan Hospital of China Academy of Chinese Medical Sciences for cholangiocarcinoma, a rare biliary tract malignancy. The program, designated PULSAR-ICON, is currently in Phase 2 clinical development. The candidate is formulated as an injection and represents a small-molecule modality approach to this difficult-to-treat indication. As of the latest disclosed milestone on 18 December 2025, the program remains active in clinical trials. The sponsor is conducting development primarily in China, with regulatory activity tracked under the NMPA (China) regulatory framework. The program is supported by multiple clinical trials registered on ClinicalTrials.gov, including the primary Phase 2 trial NCT07291947. Mechanism of action, specific molecular targets, and detailed clinical efficacy data have not yet been disclosed in available sources.

Cholangiocarcinoma represents a significant unmet medical need with poor prognosis and limited treatment options. The disease carries high mortality rates and presents substantial clinical challenges due to late-stage diagnosis and limited effective therapies. The competitive landscape for cholangiocarcinoma is increasingly crowded, with multiple Phase 3 programs from major pharmaceutical companies including Incyte (Pemigatinib, INCB 54828-302), AstraZeneca, BridgeBio Oncology (BGJ398), and Taiho Pharma (TAS-120), alongside earlier-stage candidates. The QL1706 program's positioning as a combination therapy with two active components (iparomlimab and tuvonralimab) may offer a differentiated approach to addressing resistance mechanisms or targeting complementary pathways in cholangiocarcinoma. The patient population for cholangiocarcinoma is relatively small but represents a high-value indication due to the severity of disease and lack of curative options. Commercial significance is moderate given the rare disease classification, though successful development could establish a meaningful market position in Asia, particularly China where the sponsor is based. The Phase 2 status indicates the program is still in early-to-mid stage development, with substantial clinical and regulatory work remaining before potential commercialization.

QL1706 is a small-molecule injection combining two active pharmaceutical ingredients: iparomlimab and tuvonralimab. The therapeutic class, specific mechanism of action, molecular targets, and route of administration details have not yet been disclosed. The program represents a combination approach rather than a single-agent therapy. Related therapies in development for cholangiocarcinoma include fibroblast growth factor receptor (FGFR) inhibitors such as Pemigatinib (Incyte) and BGJ398 (BridgeBio), as well as other targeted small molecules. First approval date and patent status information are not yet disclosed.

• China (NMPA): QL1706 is in clinical trials status under Chinese regulatory oversight. Multiple clinical trial registrations are active on ClinicalTrials.gov, indicating ongoing development in China.
• FDA (United States): Regulatory status not yet disclosed.
• EMA (European Union): Regulatory status not yet disclosed.
• PMDA (Japan): Regulatory status not yet disclosed.
• Clinical Trial Registry: Primary trial NCT07291947 is registered; additional supporting trials under the program include multiple NCT identifiers tracking iparomlimab and tuvonralimab development separately.

• Development Stage Risk: QL1706 remains in Phase 2, positioning it 1-2 years behind multiple Phase 3 competitors in the cholangiocarcinoma space. This timeline disadvantage is significant given the competitive intensity and potential for earlier competitors to establish market presence.
• Combination Strategy Differentiation: The dual-component formulation (iparomlimab + tuvonralimab) represents a potentially differentiated approach compared to predominantly single-agent competitors. However, clinical data demonstrating synergistic benefit or superior outcomes versus monotherapy will be essential to justify the combination strategy.
• Geographic Focus: Development appears concentrated in China under NMPA oversight, with no disclosed regulatory activity in FDA, EMA, or PMDA jurisdictions. This suggests a China-first or China-focused development strategy, which may limit global market potential but could accelerate approval timelines in the primary market.
• Data Disclosure Gap: Mechanism of action, molecular targets, and clinical efficacy data remain undisclosed. Publication of Phase 2 data will be critical to assess competitive positioning and differentiation potential.
• Expected Catalysts: Phase 2 efficacy and safety data readout, potential Phase 3 initiation decision, and regulatory feedback from NMPA are key near-term catalysts. Comparative efficacy data versus Pemigatinib or other FGFR inhibitors would be particularly valuable for competitive assessment.